Logo
x

Search

Subscribe Now

Ardelyx

Ardelyx Reports the NMPA Acceptance of NDA for Tenapanor to Treat Hyperphosphatemia in China

Ardelyx Reports the NMPA Acceptance of NDA for Tenapanor to Treat Hyperphosphatemia in China

  • July 14, 2023
Ardelyx Amends 2017 Agreement with Kyowa Kirin for Tenapanor to Treat Hyperphosphatemia in Japan

Ardelyx Amends 2017 Agreement with Kyowa Kirin for Tenapanor to Treat Hyperphosphatemia in Japan

  • April 12, 2022
Insights+: The US FDA New Drug Approvals in September and October 2019

Insights+: The US FDA New Drug Approvals in September and October 2019

  • November 15, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.